Thyroid nodules are detected in up to 70% of the population, while only 7% to 15% of them are malignant.
1,2 Ultrasonography-guided fine-needle aspiration (FNA) cytological examination has served as the criterion standard for preoperative diagnosis of thyroid nodules. Each thyroid FNA is classified into 1 of 6 diagnostic categories: (1) nondiagnostic or unsatisfactory (ND), (2) benign, (3) atypia of undetermined significance/follicular lesion of undetermined significance (AUS/FLUS), (4) follicular neoplasm/suspicious for follicular neoplasm (FN/SFN), (5) suspicious for malignancy (SFM), and (6) malignant, based on the Bethesda System for Reporting Thyroid Cytopathology.
3 Fortunately, most thyroid lesions can be correctly diagnosed as benign (70%-75%) or malignant (5%-10%). However, cytological examination cannot discriminate between benign and cancerous nodules in an estimated 30% of FNAs, categorizing them instead as AUS/FLUS, FN/SFN, or SFM, referred as indeterminate thyroid nodules, which therefore require diagnostic resections (lobectomy or total thyroidectomy) for further histopathological examination. Of indeterminate thyroid nodules, an approximate 20% will be found as malignant after diagnostic resections,
4,5 indicating the other 80% of patients will have undergone an unnecessary surgical operation. As for patients with ND FNA biopsies that contain inadequate or insufficient follicular cells for standard cytological diagnosis, additional FNA biopsy is required to repeat the cytological evaluation, resulting in delays in diagnosis and increases of stress and cost to these patients. However, patients whose nodules persistently remain ND are referred for diagnostic surgery, and approximately 12% of nodules will be found to have malignant histopathological characteristics.
3,5 Molecular assay has been evolving as an ancillary approach to assist in identifying malignant neoplasms in preoperative FNA specimens.
3,6 A broad range of tests using gene panels have shown promising performance in diagnostic accuracy, including Afirma Gene Expression Classifier,
7,8 genomic sequencing classifier,
9 and ThyroSeq v2 or v3,
10-12 but there is currently no single unequivocal test available for definitive assessment of thyroid nodules.
13 In addition, these tests are mostly accessible in limited test centers and require obtaining additional fresh FNA biopsies. A molecular assay able to use the residual tissue from routine indeterminate FNA biopsies or ND FNA specimens in a diagnostic test to reveal genetic anomalies, in parallel with the FNA cytological examination results on the same batch of FNA biopsies, could not only enhance a more definitive cytological interpretation but also redefine the clinical value of the residual FNA samples, which are considered discard after cytological examination. Such a test would likely spare these patients from the need for a repeat FNA biopsy or diagnostic operation.